Hepatitis Monthly

Published by: Kowsar

Predicting the Outcomes of Combination Therapy in Patients With Chronic Hepatitis C Using Artificial Neural Network

Forough Sargolzaee Aval 1 , Nazanin Behnaz 1 , * , Mohamad Reza Raoufy 2 and Seyed Moayed Alavian 3
Authors Information
1 Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
3 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 2014, 14 (6); e17028
  • Published Online: June 1, 2014
  • Article Type: Research Article
  • Received: December 20, 2013
  • Revised: February 15, 2014
  • Accepted: April 5, 2014
  • DOI: 10.5812/hepatmon.17028

To Cite: Sargolzaee Aval F, Behnaz N, Raoufy M R, Alavian S M. Predicting the Outcomes of Combination Therapy in Patients With Chronic Hepatitis C Using Artificial Neural Network, Hepat Mon. 2014 ;14(6):e17028. doi: 10.5812/hepatmon.17028.

Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2010; 65(2): 202-12[DOI][PubMed]
  • 2. Cooper C. Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Can J Gastroenterol. 2010; 24(6): 385-90[PubMed]
  • 3. Sporea I, Sirli R, Curescu M, Gheorghe L, Popescu A, Bota S, et al. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients. J Gastrointestin Liver Dis. 2010; 19(3): 261-4[PubMed]
  • 4. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011; 54(3): 415-21[DOI][PubMed]
  • 5. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 6. Alavian SM, Jabbari H, Daryani NE, Torabi Nami M. Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran. Hepat Mon. 2012; 12(7): 423-9[DOI]
  • 7. Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med. 2009; 29(1): 4-14[PubMed]
  • 8. Antonucci G, Angeletti C, Vairo F, Longo MA, Girardi E. Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels. J Infect Dis. 2009; 200(9): 1484-5[DOI][PubMed]
  • 9. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006; 62(6): 699-709[DOI][PubMed]
  • 10. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008; 48(6): 1753-60[DOI][PubMed]
  • 11. Saludes V, Bracho MA, Valero O, Ardevol M, Planas R, Gonzalez-Candelas F, et al. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One. 2010; 5(11)[DOI][PubMed]
  • 12. Wang CH, Mo LR, Lin RC, Kuo JJ, Chang KK, Wu JJ. Artificial neural network model is superior to logistic regression model in predicting treatment outcomes of interferon-based combination therapy in patients with chronic hepatitis C. Intervirology. 2008; 51(1): 14-20[DOI][PubMed]
  • 13. Grossi E, Buscema M. Introduction to artificial neural networks. Eur J Gastroenterol Hepatol. 2007; 19(12): 1046-54[DOI][PubMed]
  • 14. Raoufy MR, Hajizadeh S, Gharibzadeh S, Mani AR, Eftekhari P, Masjedi MR. Nonlinear model for estimating respiratory volume based on thoracoabdominal breathing movements. Respirology. 2013; 18(1): 108-16[DOI][PubMed]
  • 15. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[DOI][PubMed]
  • 16. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci. 1994; 39(6): 1273-80[PubMed]
  • 17. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 18. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007; 356(14): 1445-54[DOI][PubMed]
  • 19. Foster GR, Fried MW, Hadziyannis SJ, Chaneac M. 189 Treatment of chronic hepatitis C with peginterferon ALFA-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology. 2003; 38, Supplement: 246
  • 20. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 2006; 130(4): 1098-106[DOI][PubMed]
  • 21. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010; 30(8): 1173-80[DOI][PubMed]
  • 22. Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol. 2011; 7(2)[DOI][PubMed]
  • 23. Jun DW, Tak WY, Bae SH, Lee YJ. Recent trends in the treatment of chronic hepatitis C. Korean J Hepatol. 2012; 18(1): 22-8[DOI][PubMed]
  • 24. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010; 52(3): 864-74[DOI][PubMed]
  • 25. Fonseca-Coronado S, Vaughan G, Cruz-Rivera MY, Carpio-Pedroza JC, Ruiz-Tovar K, Ruiz-Pacheco JA, et al. Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients. J Clin Microbiol. 2011; 49(7): 2706-10[DOI][PubMed]
  • 26. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 27. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138(7): 2307-14[DOI][PubMed]
  • 28. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011; 11(12): 958-9[DOI][PubMed]
  • 29. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 30. Takayama T, Ebinuma H, Tada S, Yamagishi Y, Wakabayashi K, Ojiro K, et al. Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection. PLoS One. 2011; 6(12)[DOI][PubMed]
  • 31. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology. 2001; 33(2): 419-23[DOI][PubMed]
  • 32. Akbar HO, Al Ghamdi A, Qattan F, Fallatah HI, Al Rumani M. Chronic hepatitis C in saudi arabia: three years local experience in a university hospital. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 33. Raoufy MR, Vahdani P, Alavian SM, Fekri S, Eftekhari P, Gharibzadeh S. A novel method for diagnosing cirrhosis in patients with chronic hepatitis B: artificial neural network approach. J Med Syst. 2011; 35(1): 121-6[DOI][PubMed]
  • 34. Raoufy MR, Eftekhari P, Gharibzadeh S, Masjedi MR. Predicting arterial blood gas values from venous samples in patients with acute exacerbation chronic obstructive pulmonary disease using artificial neural network. J Med Syst. 2011; 35(4): 483-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader